Saccharomyces boulardii combined with triple therapy alter the microbiota in the eradication of helicobacter pylori infection

Abstract

Abstract To assess the effectiveness and safety of combining Saccharomyces boulardii powder with triple therapy as a primary approach for eradicating H. pylori infection, a total of 144 patients who tested positive for H. pylori and diagnosed with non-ulcer dyspepsia underwent gastroscopy at two national centers between June 2017 and March 2019. The patients were categorized into three groups using a subsection randomization method and received initial H. pylori eradication treatments. In the SRAC group, participants were administered saccharomyces boulardii powder alongside triple therapy for the first 10 days, followed by 4 extra days of saccharomyces boulardii treatment only. The BRAC group received a 10-day bismuth quadruple therapy, while the RAC group underwent a 10-day triple therapy regimen. Microbial composition, eradication rates, symptom alleviation, and adverse reactions were monitored on the 14th and 44th days post-treatment. Distinct treatment protocols exhibited varying impacts on the intestinal microecology. When employed as a primary strategy, the combination of Saccharomyces boulardii powder with triple therapy displayed notable efficacy in eradicating initial H. pylori infections among non-ulcer dyspepsia patients. Moreover, this approach demonstrated advantages in alleviating symptoms, exhibited favorable tolerance, and maintained a high level of clinical safety.